CAR T-Cell Therapy Market Size to Hit USD 128.55 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on CAR T-Cell Therapy Market

5.1. COVID-19 Landscape: CAR T-Cell Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global CAR T-Cell Therapy Market, By Target Antigen

8.1. CAR T-Cell Therapy Market, by Target Antigen

8.1.1. CD19

8.1.1.1. Market Revenue and Forecast

8.1.2. BCMA (B-cell Maturation Antigen)

8.1.2.1. Market Revenue and Forecast

8.1.3. CD22

8.1.3.1. Market Revenue and Forecast

8.1.4. GD2

8.1.4.1. Market Revenue and Forecast

8.1.5. HER2

8.1.5.1. Market Revenue and Forecast

8.1.6. GPC3

8.1.6.1. Market Revenue and Forecast

8.1.7. Others (e.g., EGFRvIII, CD7, CD123, mesothelin)

8.1.7.1. Market Revenue and Forecast

Chapter 9. Global CAR T-Cell Therapy Market, By Indication / Disease Type

9.1. CAR T-Cell Therapy Market, by Indication / Disease Type

9.1.1. Hematologic Malignancies

9.1.1.1. Market Revenue and Forecast

9.1.2. Acute Lymphoblastic Leukemia (ALL)

9.1.2.1. Market Revenue and Forecast

9.1.3. Diffuse Large B-cell Lymphoma (DLBCL)

9.1.3.1. Market Revenue and Forecast

9.1.4. Mantle Cell Lymphoma (MCL)

9.1.4.1. Market Revenue and Forecast

9.1.5. Follicular Lymphoma (FL)

9.1.5.1. Market Revenue and Forecast

9.1.6. Follicular Lymphoma (FL)

9.1.6.1. Market Revenue and Forecast

9.1.7. Chronic Lymphocytic Leukemia (CLL)

9.1.7.1. Market Revenue and Forecast

9.1.8. Chronic Lymphocytic Leukemia (CLL)

9.1.8.1. Market Revenue and Forecast

9.1.9. Other Non-Hodgkin Lymphomas (NHL)

9.1.9.1. Market Revenue and Forecast

9.1.10. Solid Tumors

9.1.10.1. Market Revenue and Forecast

9.1.11. Neuroblastoma

9.1.11.1. Market Revenue and Forecast

9.1.12. Glioblastoma

9.1.12.1. Market Revenue and Forecast

9.1.13. Breast Cancer

9.1.13.1. Market Revenue and Forecast

9.1.14. Breast Cancer

9.1.14.1. Market Revenue and Forecast

9.1.15. Breast Cancer

9.1.15.1. Market Revenue and Forecast

9.1.16. Lung Cancer

9.1.16.1. Market Revenue and Forecast

9.1.17. Prostate Cancer

9.1.17.1. Market Revenue and Forecast

9.1.18. Colorectal Cancer

9.1.18.1. Market Revenue and Forecast

9.1.19. Others

9.1.19.1. Market Revenue and Forecast

Chapter 10. Global CAR T-Cell Therapy Market, By Type of Therapy

10.1. CAR T-Cell Therapy Market, by Type of Therapy

10.1.1. Autologous CAR T-cell Therapy

10.1.1.1. Market Revenue and Forecast

10.1.2. Allogeneic CAR T-cell Therapy

10.1.2.1. Market Revenue and Forecast

Chapter 11. Global CAR T-Cell Therapy Market, By Technology / Vector Used

11.1. CAR T-Cell Therapy Market, by Technology / Vector Used

11.1.1. Viral Vectors

11.1.1.1. Market Revenue and Forecast

11.1.2. Non-viral Vectors

11.1.2.1. Market Revenue and Forecast

11.1.3. Armored CAR T-Cells (enhanced T-cell persistence/activity)

11.1.3.1. Market Revenue and Forecast

11.1.4. Dual/Multiple Antigen Targeting CAR T-Cells

11.1.4.1. Market Revenue and Forecast

11.1.5. Dual/Multiple Antigen Targeting CAR T-Cells

11.1.5.1. Market Revenue and Forecast

Chapter 12. Global CAR T-Cell Therapy Market, By Manufacturing/Delivery Method

12.1. CAR T-Cell Therapy Market, by Manufacturing/Delivery Method

12.1.1. Point-of-Care Manufacturing

12.1.1.1. Market Revenue and Forecast

12.1.2. Centralized Manufacturing

12.1.2.1. Market Revenue and Forecast

12.1.3. In vivo CAR T therapy (emerging)

12.1.3.1. Market Revenue and Forecast

12.1.4. Off-the-shelf / Ready-to-use therapies

12.1.4.1. Market Revenue and Forecast

Chapter 13. Global CAR T-Cell Therapy Market, By End User

13.1. CAR T-Cell Therapy Market, by End User

13.1.1. Hospitals

13.1.1.1. Market Revenue and Forecast

13.1.2. Cancer Treatment Centers

13.1.2.1. Market Revenue and Forecast

13.1.3. Academic & Research Institutes

13.1.3.1. Market Revenue and Forecast

13.1.4. Specialty Clinics

13.1.4.1. Market Revenue and Forecast

13.1.5. Contract Development and Manufacturing Organization

13.1.5.1. Market Revenue and Forecast

Chapter 14. Global CAR T-Cell Therapy Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Target Antigen

14.1.2. Market Revenue and Forecast, by Indication / Disease Type

14.1.3. Market Revenue and Forecast, by Type of Therapy

14.1.4. Market Revenue and Forecast, by Technology / Vector Used

14.1.5. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.1.6. Market Revenue and Forecast, by End User

14.1.7. U.S.

14.1.7.1. Market Revenue and Forecast, by Target Antigen

14.1.7.2. Market Revenue and Forecast, by Indication / Disease Type

14.1.7.3. Market Revenue and Forecast, by Type of Therapy

14.1.7.4. Market Revenue and Forecast, by Technology / Vector Used

14.1.8. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.1.8.1. Market Revenue and Forecast, by End User

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Target Antigen

14.1.9.2. Market Revenue and Forecast, by Indication / Disease Type

14.1.9.3. Market Revenue and Forecast, by Type of Therapy

14.1.9.4. Market Revenue and Forecast, by Technology / Vector Used

14.1.10. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.1.11. Market Revenue and Forecast, by End User

14.1.11.1.

14.2. Europe

14.2.1. Market Revenue and Forecast, by Target Antigen

14.2.2. Market Revenue and Forecast, by Indication / Disease Type

14.2.3. Market Revenue and Forecast, by Type of Therapy

14.2.4. Market Revenue and Forecast, by Technology / Vector Used

14.2.5. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.2.6. Market Revenue and Forecast, by End User

14.2.7.

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Target Antigen

14.2.8.2. Market Revenue and Forecast, by Indication / Disease Type

14.2.8.3. Market Revenue and Forecast, by Type of Therapy

14.2.9. Market Revenue and Forecast, by Technology / Vector Used

14.2.10. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.2.10.1. Market Revenue and Forecast, by End User

14.2.11. Germany

14.2.11.1. Market Revenue and Forecast, by Target Antigen

14.2.11.2. Market Revenue and Forecast, by Indication / Disease Type

14.2.11.3. Market Revenue and Forecast, by Type of Therapy

14.2.12. Market Revenue and Forecast, by Technology / Vector Used

14.2.13. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.2.14. Market Revenue and Forecast, by End User

14.2.14.1.

14.2.15. France

14.2.15.1. Market Revenue and Forecast, by Target Antigen

14.2.15.2. Market Revenue and Forecast, by Indication / Disease Type

14.2.15.3. Market Revenue and Forecast, by Type of Therapy

14.2.15.4. Market Revenue and Forecast, by Technology / Vector Used

14.2.16. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.2.16.1. Market Revenue and Forecast, by End User

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Forecast, by Target Antigen

14.2.17.2. Market Revenue and Forecast, by Indication / Disease Type

14.2.17.3. Market Revenue and Forecast, by Type of Therapy

14.2.17.4. Market Revenue and Forecast, by Technology / Vector Used

14.2.18. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.2.18.1. Market Revenue and Forecast, by End User

14.3. APAC

14.3.1. Market Revenue and Forecast, by Target Antigen

14.3.2. Market Revenue and Forecast, by Indication / Disease Type

14.3.3. Market Revenue and Forecast, by Type of Therapy

14.3.4. Market Revenue and Forecast, by Technology / Vector Used

14.3.5. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.3.6. Market Revenue and Forecast, by End User

14.3.7. India

14.3.7.1. Market Revenue and Forecast, by Target Antigen

14.3.7.2. Market Revenue and Forecast, by Indication / Disease Type

14.3.7.3. Market Revenue and Forecast, by Type of Therapy

14.3.7.4. Market Revenue and Forecast, by Technology / Vector Used

14.3.8. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.3.9. Market Revenue and Forecast, by End User

14.3.10. China

14.3.10.1. Market Revenue and Forecast, by Target Antigen

14.3.10.2. Market Revenue and Forecast, by Indication / Disease Type

14.3.10.3. Market Revenue and Forecast, by Type of Therapy

14.3.10.4. Market Revenue and Forecast, by Technology / Vector Used

14.3.11. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.3.11.1. Market Revenue and Forecast, by End User

14.3.12. Japan

14.3.12.1. Market Revenue and Forecast, by Target Antigen

14.3.12.2. Market Revenue and Forecast, by Indication / Disease Type

14.3.12.3. Market Revenue and Forecast, by Type of Therapy

14.3.12.4. Market Revenue and Forecast, by Technology / Vector Used

14.3.12.5. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.3.12.6. Market Revenue and Forecast, by End User

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Forecast, by Target Antigen

14.3.13.2. Market Revenue and Forecast, by Indication / Disease Type

14.3.13.3. Market Revenue and Forecast, by Type of Therapy

14.3.13.4. Market Revenue and Forecast, by Technology / Vector Used

14.3.13.5. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.3.13.6. Market Revenue and Forecast, by End User

14.4. MEA

14.4.1. Market Revenue and Forecast, by Target Antigen

14.4.2. Market Revenue and Forecast, by Indication / Disease Type

14.4.3. Market Revenue and Forecast, by Type of Therapy

14.4.4. Market Revenue and Forecast, by Technology / Vector Used

14.4.5. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.4.6. Market Revenue and Forecast, by End User

14.4.7. GCC

14.4.7.1. Market Revenue and Forecast, by Target Antigen

14.4.7.2. Market Revenue and Forecast, by Indication / Disease Type

14.4.7.3. Market Revenue and Forecast, by Type of Therapy

14.4.7.4. Market Revenue and Forecast, by Technology / Vector Used

14.4.8. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.4.9. Market Revenue and Forecast, by End User

14.4.10. North Africa

14.4.10.1. Market Revenue and Forecast, by Target Antigen

14.4.10.2. Market Revenue and Forecast, by Indication / Disease Type

14.4.10.3. Market Revenue and Forecast, by Type of Therapy

14.4.10.4. Market Revenue and Forecast, by Technology / Vector Used

14.4.11. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.4.12. Market Revenue and Forecast, by End User

14.4.13. South Africa

14.4.13.1. Market Revenue and Forecast, by Target Antigen

14.4.13.2. Market Revenue and Forecast, by Indication / Disease Type

14.4.13.3. Market Revenue and Forecast, by Type of Therapy

14.4.13.4. Market Revenue and Forecast, by Technology / Vector Used

14.4.13.5. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.4.13.6. Market Revenue and Forecast, by End User

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Forecast, by Target Antigen

14.4.14.2. Market Revenue and Forecast, by Indication / Disease Type

14.4.14.3. Market Revenue and Forecast, by Type of Therapy

14.4.14.4. Market Revenue and Forecast, by Technology / Vector Used

14.4.14.5. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.4.14.6. Market Revenue and Forecast, by End User

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Target Antigen

14.5.2. Market Revenue and Forecast, by Indication / Disease Type

14.5.3. Market Revenue and Forecast, by Type of Therapy

14.5.4. Market Revenue and Forecast, by Technology / Vector Used

14.5.5. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.5.6. Market Revenue and Forecast, by End User

14.5.7. Brazil

14.5.7.1. Market Revenue and Forecast, by Target Antigen

14.5.7.2. Market Revenue and Forecast, by Indication / Disease Type

14.5.7.3. Market Revenue and Forecast, by Type of Therapy

14.5.7.4. Market Revenue and Forecast, by Technology / Vector Used

14.5.8. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.5.8.1. Market Revenue and Forecast, by End User

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Target Antigen

14.5.9.2. Market Revenue and Forecast, by Indication / Disease Type

14.5.9.3. Market Revenue and Forecast, by Type of Therapy

14.5.9.4. Market Revenue and Forecast, by Technology / Vector Used

14.5.9.5. Market Revenue and Forecast, by Manufacturing/Delivery Method

14.5.9.6. Market Revenue and Forecast, by End User

Chapter 15. Company Profiles

15.1. Johnson & Johnson Services, Inc.

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. ALLOGENE THERAPEUTICS

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Lonza

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Aurora Biopharma

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Cartesian Therapeutics, Inc

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Novartis

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Bristol-Myers Squibb company

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Gilead Sciences

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Curocell Inc

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. JW Therapeutics

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global CAR T-cell therapy market size was estimated at USD 10.39 billion in 2024 and it is expected to reach around USD 128.55 billion by 2034.

The global CAR T-cell therapy market is poised to grow at a CAGR of 29.10% from 2025 to 2034.

The major players operating in the CAR T-cell therapy market are Johnson & Johnson Services, Inc., ALLOGENE THERAPEUTICS, Lonza, Aurora Biopharma, Cartesian Therapeutics, Inc., Novartis, Bristol-Myers Squibb company, Gilead Sciences, Curocell Inc, JW Therapeutics and Others.

The driving factors of the CAR T-cell therapy market are the increasing number of CAR-T cell therapy product approvals, increase in cancer cases and increased demand for CAR-T cell therapy supplies.

North America region will lead the global CAR T-cell therapy market during the forecast period 2025 to 2034.